SAN DIEGO, June 18 (Korea Bizwire) — Crown Bioscience today announced their innovative AACR 2020 conference and tradeshow. The virtual event, which runs from June 22-25, will incorporate all of the features of a major scientific conference, with keynote speakers, access to CrownBio’s AACR 2020 posters, as well as a tradeshow booth. To coincide with [...]
SAN DIEGO, June 9 (Korea Bizwire) — Crown Bioscience today announced the presentation of new, proprietary NAFLD/NASH preclinical model development data. The data will be available at the American Diabetes Association (ADA) 80th Scientific Sessions, as well as CrownBio’s own complementary virtual event. The new data shares development of NAFLD/NASH models generated through dietary modifications across [...]
SAN DIEGO, May 26 (Korea Bizwire) — Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht Organoid Technology (HUB) patient-derived organoids (PDO). This marks a significant milestone in the development of CrownBio’s innovative organoid platform and the first, large-scale commercial availability of HUB PDO for oncology drug [...]
SAN DIEGO, April 14 (Korea Bizwire) — Crown Bioscience has announced the appointment of Jean-Pierre Wery, PhD as executive chairman of the board effective immediately. Dr. Wery will also serve as chief technology officer (CTO) for JSR Life Sciences, LLC. JSR acquired CrownBio in 2018 to expand their life science portfolio to serve the preclinical [...]
SAN DIEGO, March 10 (Korea Bizwire) — Crown Bioscience today announced the launch of two new liver fibrosis rodent models, allowing more rapid and cost-effective evaluation of the preclinical effects of NASH and anti-fibrotic treatments on acute liver injury, advanced fibrosis, and/or fibrosis reversal. The two models encompass fibrosis induced by carbon tetrachloride and a [...]
SAN DIEGO, Oct. 28 (Korea Bizwire) — Crown Bioscience today announced a strategic collaboration with NEXT Oncology to provide new clinically-relevant PDX models for preclinical drug development. The agreement establishes CrownBio as the exclusive global commercialization partner for all primary tumor PDX models generated by NEXT Oncology for the next five years. These models will [...]
SAN DIEGO, Oct. 17 (Korea Bizwire) — Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity and speed of preclinical drug discovery. The initial phase of the platform launch features the first commercially available 3D in vitro PDX-derived organoid (PDXO) models generated from CrownBio’s [...]
SAN DIEGO, Jun. 12 (Korea Bizwire) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, today announced four new preclinical translational NASH models in development. NASH is a degenerative liver disease that affects up to 12 percent of the adult population [...]
SAN DIEGO, Mar. 28 (Korea Bizwire) — Crown Bioscience, a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation and autoimmune, cardiovascular and metabolic disease research announced today that parent company, JSR Corporation, has entered into a strategic partnership with Hubrecht Organoid Technology (HUB). The agreement provides CrownBio, a wholly [...]
SAN DIEGO, Dec. 18 (Korea Bizwire) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has recently announced the expansion of its existing translational oncology research capacity by opening a new site in Suzhou, Jiangsu, China. The large amount of data [...]